{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:53:38Z","timestamp":1790855618984,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s11912-021-01068-0","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T20:18:04Z","timestamp":1620073084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cardiovascular Toxicities of CAR T-cell Therapy"],"prefix":"10.1007","volume":"23","author":[{"given":"Nikita P.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Doukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-8578","authenticated-orcid":false,"given":"Nausheen","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"issue":"1","key":"1068_CR1","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10179","volume":"6","author":"K Perica","year":"2015","unstructured":"Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. 2015;6(1):e0004.","journal-title":"Rambam Maimonides Med J"},{"key":"1068_CR2","unstructured":"Tisagenlecleucel STN 125646 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Aug 2017. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel. Accessed 30 Jan 2021."},{"key":"1068_CR3","unstructured":"Axicabtagene Ciloleucel STN BL 125643 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Oct 2017. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel. Accessed 30 Jan 2021."},{"key":"1068_CR4","unstructured":"Brexucabtagene Autoleucel STN BL 125703 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Jul 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel. Accessed 30 Jan 2021."},{"key":"1068_CR5","unstructured":"Lisocabtagene Maraleucel STN BLA 125714 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Feb 2021. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi-lisocabtagene-maraleucel. Accessed 6 Feb 2021."},{"issue":"2","key":"1068_CR6","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124\u2013e31.","journal-title":"Crit Care Med"},{"issue":"8","key":"1068_CR7","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","volume":"24","author":"DS Burstein","year":"2018","unstructured":"Burstein DS, Maude S, Grupp S, Griffis H, Rossano J, Lin K. Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience. Biol Blood Marrow Transplant. 2018;24(8):1590\u20135 This is the first retrospective study of adverse cardiovascular events in pediatric and young adult patients treated with CAR T-cell therapy. 6\/7 patients who developed LV dysfunction at hospital discharge had recovered by 6 months, demonstrating rare persistent LV dysfunction.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"1068_CR8","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74(25):3099\u2013108 This is the first retrospective study of adverse cardiovascular events in adults treated with CAR T-cell therapy. It is also the first study to suggest a role for troponin as a predict biomarker to identify patients at higher risk for cardiac events who may benefit from earlier treatment with tocilizumab.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1068_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","volume":"2","author":"B Lefebvre","year":"2020","unstructured":"Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M. Cardiovascular effects of CAR T cell therapy: a retrospective study. JACC CardioOncol. 2020;2(2):193\u2013203 This study demonstrated a higher prevalence of heart failure (15%) in adult patients treated with CAR T-cell therapy, 60% of whom were previously treated with anthracyclines.","journal-title":"JACC CardioOncol"},{"issue":"2","key":"1068_CR10","doi-asserted-by":"publisher","first-page":"e001159","DOI":"10.1136\/jitc-2020-001159","volume":"8","author":"H Shalabi","year":"2020","unstructured":"Shalabi H, Sachdev V, Kulshreshtha A, Cohen JW, Yates B, Rosing DR, et al. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. Journal for ImmunoTherapy of Cancer. 2020;8(2):e001159. https:\/\/doi.org\/10.1136\/jitc-2020-001159This study showed a statistically significant lower baseline GLS in patients who developed cardiac dysfunction following CAR T-cell infusion compared to patients who did not develop cardiac dysfunction.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"17","key":"1068_CR11","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","volume":"142","author":"S Ganatra","year":"2020","unstructured":"Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, et al. Chimeric antigen receptor T-cell therapy\u2013associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation. 2020;142(17):1687\u201390 Most recent retrospective review of adverse cardiovascular events in adult patients treated with CAR T-cell therapy, ~10% of patients developing LV dysfunction which was associated with pre-existing cardiac risk factors including coronary artery disease, hyperlipidemia, and baseline treatment with renin-angiotensin inhibitors and beta blockers.","journal-title":"Circulation"},{"issue":"7","key":"1068_CR12","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.1991.9.7.1215","volume":"9","author":"AC Braverman","year":"1991","unstructured":"Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991;9(7):1215\u201323.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1068_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/archinte.1981.00340060066015","volume":"141","author":"JS Gottdiener","year":"1981","unstructured":"Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758\u201363.","journal-title":"Arch Intern Med"},{"issue":"1","key":"1068_CR14","doi-asserted-by":"crossref","first-page":"232470961348034","DOI":"10.1177\/2324709613480346","volume":"1","author":"S Dhesi","year":"2013","unstructured":"Dhesi S, Chu MP, Blevins G, Paterson I, Larratt L, Oudit GY, et al. Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management. J Investig Med High Impact Case Rep. 2013;1(1):2324709613480346.","journal-title":"J Investig Med High Impact Case Rep"},{"key":"1068_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2016","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2016;4:92\u2013101.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"26","key":"1068_CR16","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017\u201323.","journal-title":"Blood."},{"issue":"Supplement_1","key":"1068_CR17","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1182\/blood-2019-127566","volume":"134","author":"CR Bachier","year":"2019","unstructured":"Bachier CR, Palomba ML, Abramson JS, Andreadis C, Sehgal AR, Godwin J, et al. Outpatient treatment with lisocabtagene maraleucel (liso-cel) in three ongoing clinical studies in relapsed\/refractory (R\/R) B cell non-Hodgkin lymphoma (NHL), including second-line transplant ineligible patients: transcend NHL 001, outreach, and PILOT. Blood. 2019;134(Supplement_1):2868.","journal-title":"Blood"},{"key":"1068_CR18","unstructured":"Tisagenlecleucel STN 125646 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. May 2018. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel. Accessed 30 Jan 2021."},{"issue":"5","key":"1068_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"1068_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"26","key":"1068_CR21","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"1068_CR22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"10254","key":"1068_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicenter seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet."},{"key":"1068_CR24","unstructured":"Blinatumomab STN BL 125557 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Dec 2014. https:\/\/www.fda.gov\/media\/90343\/download. Accessed 30 Jan 2021."},{"issue":"9","key":"1068_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1609783.","journal-title":"N Engl J Med"},{"issue":"1","key":"1068_CR26","first-page":"97","volume":"2","author":"AK Ghosh","year":"2020","unstructured":"Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T cell therapy\u2013related cardiovascular outcomes and management. JACC: CardioOncology. 2020;2(1):97\u2013109 This review suggests a screening and monitoring program for CAR T-cell therapy at the University College of London Hospital.","journal-title":"JACC: CardioOncology"},{"key":"1068_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"issue":"1","key":"1068_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"1068_CR29","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943\u20137.","journal-title":"Oncologist."},{"issue":"Supplement_1","key":"1068_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1182\/blood-2019-123051","volume":"134","author":"S Liu","year":"2019","unstructured":"Liu S, Deng B, PAN J, Yin Z, Lin Y, Ling Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood. 2019;134(Supplement_1):228.","journal-title":"Blood"},{"issue":"2","key":"1068_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","volume":"33","author":"EJM Grigor","year":"2019","unstructured":"Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, et al. Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019;33(2):98\u2013110.","journal-title":"Transfus Med Rev"},{"key":"1068_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.intimp.2016.10.017","volume":"41","author":"B Darvishi","year":"2016","unstructured":"Darvishi B, Farahmand L, Jalili N, Majidzadeh-A K. Blinatumomab provoked fatal heart failure. Int Immunopharmacol. 2016;41:42\u20136. https:\/\/doi.org\/10.1016\/j.intimp.2016.10.017.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"1068_CR33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation. 2019;25(4):625\u201338.","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"25","key":"1068_CR34","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1016\/j.jacc.2019.10.028","volume":"74","author":"P Lancellotti","year":"2019","unstructured":"Lancellotti P, Moonen M, Galderisi M. Chimeric antigen receptor T-cells and cardiovascular toxicity: cause for concern? J Am Coll Cardiol. 2019;74(25):3109\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1068_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11912-018-0690-1","volume":"20","author":"A Asnani","year":"2018","unstructured":"Asnani A. Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Curr Oncol Rep. 2018;20(6):44.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"1068_CR36","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863\u201371.","journal-title":"Blood."},{"issue":"1","key":"1068_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26(1):26\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1068_CR38","doi-asserted-by":"crossref","unstructured":"Titov A, Valiullina A, Zmievskaya E, Zaikova E, Petukhov A, Miftakhova R, et al. Advancing CAR T-cell therapy for solid tumors: lessons learned from lymphoma treatment. Cancers (Basel). 2020;12(1).","DOI":"10.3390\/cancers12010125"},{"issue":"12","key":"1068_CR39","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","volume":"15","author":"S Ma","year":"2019","unstructured":"Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548\u201360.","journal-title":"Int J Biol Sci"},{"issue":"8","key":"1068_CR40","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893\u2013911.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1068_CR41","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.currproblcancer.2018.05.005","volume":"42","author":"M Awadalla","year":"2018","unstructured":"Awadalla M, Hassan MZO, Alvi RM, Neilan TG. Advanced imaging modalities to detect cardiotoxicity. Curr Probl Cancer. 2018;42(4):386\u201396.","journal-title":"Curr Probl Cancer"},{"issue":"25 Pt A","key":"1068_CR42","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","volume":"63","author":"P Thavendiranathan","year":"2014","unstructured":"Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751\u201368.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1068_CR43","first-page":"515","volume":"2","author":"AJ Kanelidis","year":"2020","unstructured":"Kanelidis AJ, Raikhelkar J, Kim G, Sayer G, Bishop MR, Polonsky TS, et al. CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy. JACC: CardioOncology. 2020;2(3):515\u20138.","journal-title":"JACC: CardioOncology"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01068-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-021-01068-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01068-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T14:40:50Z","timestamp":1623940850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-021-01068-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1007\/s11912-021-01068-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"31 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has any potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"78"}}